BridgeMD
N-acetylcysteine for the treatment of cannabis dependence: working mechanisms
EU CTIS ID: 2024-519855-27-00
What this study is testing
To evaluate the working mechanisms of N-acetylcysteine for the treatment of cannabis dependence
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Males, aged 18-45 years
- Current DSM-IV diagnosis of cannabis dependence
- >1 week detoxified and abstinent
- Able to provide written informed consent and to comply with study procedures
- Dutch speaking (Dutch as primary language)
You likely can't join if
- Currently dependent on any substance other than cannabis, alcohol or nicotine
- History of any major internal disease (including diabetes, cardiovascular disease, lung disease, liver or kidney disease)
- An active or any history of neurological disorder, including but not limited to seizure disorder, epilepsy, stroke, neurological disease, cognitive impairment, head trauma with prolonged loss of consciousness (>10 minutes), or migraine headaches
- An active or a history of a psychiatric disorder including, but not limited to, depression, schizophrenia, bipolar disorder, anxiety, or other psychiatric disorders
- Asthma
- Known hypersensitivity or allergy to n-acetylcysteine, or receiving chronic therapy with medication that could interact adversely with n-acetylcysteine within 30 days prior to randomization (i.e., nitroglycerin, ACE inhibitors or antihypertensive drugs, anti-coagulants)
See the full eligibility criteria
- Males, aged 18-45 years
- Current DSM-IV diagnosis of cannabis dependence
- >1 week detoxified and abstinent
- Able to provide written informed consent and to comply with study procedures
- Dutch speaking (Dutch as primary language)
- Currently dependent on any substance other than cannabis, alcohol or nicotine
- History of any major internal disease (including diabetes, cardiovascular disease, lung disease, liver or kidney disease)
- An active or any history of neurological disorder, including but not limited to seizure disorder, epilepsy, stroke, neurological disease, cognitive impairment, head trauma with prolonged loss of consciousness (>10 minutes), or migraine headaches
- An active or a history of a psychiatric disorder including, but not limited to, depression, schizophrenia, bipolar disorder, anxiety, or other psychiatric disorders
- Asthma
- Known hypersensitivity or allergy to n-acetylcysteine, or receiving chronic therapy with medication that could interact adversely with n-acetylcysteine within 30 days prior to randomization (i.e., nitroglycerin, ACE inhibitors or antihypertensive drugs, anti-coagulants)
- Exclusion criteria for MRI: having metal in the body and/or having claustrophobia
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.